Trelegy™ Ellipta® (fluticasone furoate/ umeclidinium/vilanterol) – New drug approval
September 18, 2017 – GlaxoSmithKline and Innoviva and Theravance Biopharma announced the FDA approval of Trelegy Ellipta (fluticasone furoate [FF]/umeclidinium [UMEC]/vilanterol [VI]), for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, who are on a fixed-dose combination of Breo® Ellipta® (FF/VI) for airflow obstruction and reducing exacerbations in whom additional treatment of airflow obstruction is desired or for patients who are already receiving Incruse® Ellipta® (UMEC) and a fixed-dose combination of FF and VI.
Top